Any new coronavirus vaccine that works well and is safe will still have the daunting challenge of needing to be produced to scale in a very short amount of time. It will also have to be safely delivered...

South Australian researchers working with Oracle Cloud technology and vaccine technology developed by local company Vaxine Pty Ltd are testing a vaccine candidate against the SARS-CoV-2 coronavirus responsible...

Clinical-stage biotechnology company, Vaxart today  it had produced five COVID-19 vaccine candidates for testing in its preclinical models.  Each of the COVID-19 vaccine constructs is based on a different...

Johnson & Johnson today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020. They expect to initiate human clinical studies  at...

Valneva SE announced this week that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and agreed on the clinical development plan towards licensure...

An experimental vaccine designed to protect against many flu virus strains has yielded promising results in an efficacy trial. NIAID investigator Matthew J. Memoli, M.D., designed and led the trial, which...

Takeda Pharmaceutical Company Limited today announced that The Lancet published two papers related to Takeda’s dengue vaccine candidate (TAK-003), reporting on results from the 18-month analysis of...

A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI)...

By NewsDesk  @infectiousdiseasenews Seqirus announced this week that the U.S. Food and Drug Administration (FDA) has approved the first adjuvanted quadrivalent influenza vaccine, FLUAD® QUADRIVALENT...

By NewsDesk  @infectiousdiseasenews A University of Queensland team has met a key milestone in their fast-tracked research to develop a vaccine for the coronavirus, COVID-19. In just three weeks, the...